by Truveta staff | Apr 4, 2024 | Data
US spending on medical devices and in-vitro diagnostics totals more than $199 billion a year, with most of the costs associated with clinical development. Label expansion provides a pathway for recouping costs associated with the device development process by...
by Truveta staff | Apr 2, 2024 | Data
A common misconception is that drugs and devices must gain explicit approval from the FDA for each specific use before healthcare providers can employ them. However, a practice known as off-label use challenges this notion, revealing a broader landscape of treatment...
by Truveta Research | Apr 2, 2024 | Research, Research Insights
There was a decrease in the rate of amphetamine/dextroamphetamine (Adderall) prescription fills per eligible population starting in the fall of 2022; prescription fill rates were 11.4% lower in the first five months of 2023 compared to the first five months of 2022....
by Truveta staff | Mar 29, 2024 | Research
Prior to the new Medicare guidelines going into effect, Truveta Research and Zeke Emanuel, MD, PhD from the University of Pennsylvania, explored the first-time prescribing and dispensing of anti-obesity GLP-1 RA medications for US adults aged 60 to 69 with obesity or...
by Truveta staff | Mar 12, 2024 | Data
Stories from women whose endometriosis pain has been dismissed are devastatingly common. A typical woman in the United States will wait 10 years after her symptoms first appear to receive an endometriosis diagnosis. This delay is rooted in a pervasive lack of...
